Table 4.

Treatment-emergent adverse events after treatment with itopride

Adverse event	Itopride
	150 mg ER once daily (fasting) (n=24)	150 mg ER once daily (fed) (n=23)	50 mg IR three times daily (fasting) (n=23)
Any adverse event	3 (12.5)	4 (17.4)	1 (4.3)
Ear disorders	1 (4.2)	0 (0)	0 (0)
Ear disorder	1 (4.2)	0 (0)	0 (0)
Gastrointestinal disorders	1 (4.2)	0 (0)	1 (4.3)
Nausea	1 (4.2)	0 (0)	0 (0)
Abdominal pain	1 (4.2)	0 (0)	0 (0)
Diarrhea	0 (0)	0 (0)	1 (4.3)
General disorders and administration site conditions	1 (4.2)	0 (0)	0 (0)
General physical condition	1 (4.2)	0 (0)	0 (0)
Musculoskeletal and connective tissue disorders	1 (4.2)	1 (4.3)	0 (0)
Musculoskeletal stiffness	0 (0)	1 (4.3)	0 (0)
Muscle tightness	1 (4.2)	0 (0)	0 (0)
Nervous system disorders	1 (4.2)	2 (8.7)	0 (0)
Headache	0 (0)	1 (4.3)	0 (0)
Vasovagal syncope	1 (4.2)	0 (0)	0 (0)
Dizziness	1 (4.2)	1 (4.3)	0 (0)
Respiratory, thoracic, and mediastinal disorders	2 (8.3)	1 (4.3)	0 (0)
Dyspnea	1 (4.2)	0 (0)	0 (0)
Sputum	1 (4.2)	0 (0)	0 (0)
Rhinorrhea	0 (0)	1 (4.3)	0 (0)
Skin and subcutaneous tissue disorders	0 (0)	1 (4.3)	0 (0)
Rash	0 (0)	1 (4.3)	0 (0)

Note: Data are shown as number of subjects (%).

Abbreviations: ER, extended-release; IR, immediate-release.